FX06 for COVID-19: real-time analysis

Download Image

Post

c19early.org

FX06 for COVID-19

1 study with 49 patients

Serious outcome risk

FX06

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 FX06 studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−10%

Mortality (1)−10%

RCTs (1)−10%

Late (1)−10%

00.511.5+

← FX06
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Aug 29 2023	Guérin et al., Critical Care, doi:10.1186/s13054-023-04616-1	FX06 to rescue SARS-CoV-2-induced acute respiratory distress syndrome: a randomized clinical trial
Aug 29 2023	10% higher mortality (p=1). RCT 49 patients with COVID-19-associated ARDS showing no significant effect of FX06 on vascular leakage or mortality.